{"id":993405,"date":"2026-08-11T10:11:03","date_gmt":"2026-08-11T14:11:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/"},"modified":"2026-08-11T10:11:03","modified_gmt":"2026-08-11T14:11:03","slug":"moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/","title":{"rendered":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">TEL AVIV, Israel, Aug.  11, 2026  (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody\u2019s Ratings has upgraded Teva\u2019s corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook.\u00a0<\/p>\n<p>Moody\u2019s states that the upgrade reflects the ongoing success of Teva\u2019s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody\u2019s also noted Teva\u2019s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months.\u00a0<\/p>\n<p>\u201cMoody\u2019s upgrade to investment grade marks\u00a0a\u00a0major\u00a0milestone in Teva\u2019s transformation journey and further validates the progress we&#8217;re making through our Pivot to Growth strategy,\u201d said Eli Kalif,\u00a0Teva\u2019s\u00a0Chief Financial Officer.\u00a0\u201cThis recognition, together with Fitch\u2019s upgrade in May,\u00a0reflects years of disciplined execution, continued\u00a0debt\u00a0reduction\u00a0and a stronger financial profile. It enhances Teva\u2019s financial flexibility and access to a broader base of investors as we continue to invest in growth, advance innovation for patients and create long-term value for our stakeholders.\u201d\u00a0<\/p>\n<p>Moody\u2019s\u00a0investment-grade rating upgrade follows the recent upgrade by Fitch Ratings in May\u00a02026, further strengthening Teva\u2019s credit standing and supporting its eligibility for inclusion in leading fixed-income indices.<\/p>\n<p align=\"justify\">\n        <strong>About Teva<\/strong><br \/>\n        <br \/>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva\u2019s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients\u2019 needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=acCAqoGX2jbulcD4KN9VAr-zyBdeGHPeyIg41mS9iU3sTIHMUx3LWrXsEaEsskWuZ00_DlxTdabbu44ROjx-ncyx2klDCp_FGm5H7G_OE70=\" rel=\"nofollow\" target=\"_blank\">www.tevapharm.com<\/a>.<\/p>\n<p>\n        <strong>Teva Cautionary Note Regarding Forward Looking Statements\u00a0<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management\u2019s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as \u201cshould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve\u201d and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to continue and improve our financial ratings; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; compliance, regulatory and litigation matters; financial, economic and other risks; and other factors discussed in this Press Release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned \u201cRisk Factors,\u201d \u201cOther Information\u201d and \u201cForward-looking Statements.\u201d Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.<\/p>\n<table align=\"left\" style=\"border-collapse: collapse;width:986.823px;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:148.021px;min-width:15%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Teva Media<br \/>Inquiries<\/strong>\n          <\/td>\n<td style=\"max-width:85%;width:838.802px;min-width:85%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:TevaCommunicationsNorthAmerica@tevapharm.com\" rel=\"nofollow\" target=\"_blank\">TevaCommunicationsNorthAmerica@tevapharm.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Teva Investor<br \/>Relations<br \/>Inquiries<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:TevaIR@Tevapharm.com\" rel=\"nofollow\" target=\"_blank\">TevaIR@Tevapharm.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Mzc1OTljNTEtNTFiNi00ZjgxLWIxNjItNWYyYjJhZDNlODk4LTEwMTQ2NTAtMjAyNi0wOC0xMS1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody\u2019s Ratings has upgraded Teva\u2019s corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook.\u00a0 Moody\u2019s states that the upgrade reflects the ongoing success of Teva\u2019s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody\u2019s also noted Teva\u2019s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months.\u00a0 \u201cMoody\u2019s upgrade to investment grade marks\u00a0a\u00a0major\u00a0milestone in Teva\u2019s transformation journey and further validates the progress we&#8217;re &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-993405","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody\u2019s Ratings has upgraded Teva\u2019s corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook.\u00a0 Moody\u2019s states that the upgrade reflects the ongoing success of Teva\u2019s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody\u2019s also noted Teva\u2019s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months.\u00a0 \u201cMoody\u2019s upgrade to investment grade marks\u00a0a\u00a0major\u00a0milestone in Teva\u2019s transformation journey and further validates the progress we&#8217;re &hellip; Continue reading &quot;Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T14:11:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy\",\"datePublished\":\"2026-08-11T14:11:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/\",\"name\":\"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\",\"datePublished\":\"2026-08-11T14:11:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk","og_description":"TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody\u2019s Ratings has upgraded Teva\u2019s corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook.\u00a0 Moody\u2019s states that the upgrade reflects the ongoing success of Teva\u2019s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody\u2019s also noted Teva\u2019s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months.\u00a0 \u201cMoody\u2019s upgrade to investment grade marks\u00a0a\u00a0major\u00a0milestone in Teva\u2019s transformation journey and further validates the progress we&#8217;re &hellip; Continue reading \"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-11T14:11:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy","datePublished":"2026-08-11T14:11:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/","name":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==","datePublished":"2026-08-11T14:11:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzA2MiM0MDI0ODYwNTAjMjAwMzA3Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moody\u2019s Ratings\u00a0Upgrades Teva to Investment Grade,\u00a0Reflecting the\u00a0Ongoing\u00a0Execution\u00a0of\u00a0Pivot\u00a0to\u00a0Growth\u00a0Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=993405"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993405\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=993405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=993405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=993405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}